Long-term hormone therapy and radiation is cost-effective for patients with locally advanced prostate carcinoma

Cancer

Volumn 106, Issue 1, 2006, Pages 51-57

  Konski, Andre ^a   Watkins Bruner, Deborah ^a   Brereton, Harmar ^b   Feigenberg, Steven ^a   Hanks, Gerald ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b Mercy Hospital   (United States)

Author keywords

Androgen deprivation; Cost effectiveness; Prostate carcinoma; Quality adjusted life years

Indexed keywords

ANDROGEN; FLUTAMIDE; GOSERELIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVANCED CANCER; ARTICLE; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; COST EFFECTIVENESS ANALYSIS; HORMONE RESPONSE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICARE; PRIORITY JOURNAL; PROSTATE CARCINOMA; QUALITY ADJUSTED LIFE YEAR; SALVAGE THERAPY; SURVIVAL RATE;

ADENOCARCINOMA; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; COMBINED MODALITY THERAPY; COST-BENEFIT ANALYSIS; FLUTAMIDE; GOSERELIN; HUMANS; MALE; MARKOV CHAINS; MONTE CARLO METHOD; NEOADJUVANT THERAPY; PROSTATIC NEOPLASMS; QUALITY-ADJUSTED LIFE YEARS; RADIOTHERAPY, CONFORMAL; RANDOMIZED CONTROLLED TRIALS;

EID: 29744455808     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21575     Document Type: Article

References (23)

1. Pilepich MV, Caplan R, Byhardt RW, et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol. 1997;15:1013-1021.
2. Pilepich MV, Winter K, Lawton C, et al. Androgen suppression adjuvant to radiotherapy in carcinoma of the prostate, long-term results of Phase III RTOG study 85-31. Int J Radiat Oncol Biol Phys. 2003;57(2 Suppl):S172-S173.
3. Hanks GE, Pajak TF, Porter A, et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol. 2003;21:3972-3978.
4. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1997;337:295-300.
5. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a Phase III randomised trial. Lancet. 2002;360:103-106.
6. Pilepich MV, Winger K, Lawton C, et al. Phase III trial of androgen suppression adjuvant to definitive radiotherapy. Long term results of RTOG study 85-31 [abstract 1530]. Proc Am Soc Clin Oncol. 2003;22:381.
7. Krahn M, Ritvo P, Irvine J, et al. Patient and community preferences for outcomes in prostate cancer: implications for clinical policy. Med Care. 2003;41:153-164.
8. Hummel S, Paisley S, Morgan A, Currie E, Brewer N. Clinical and cost-effectiveness of new and emerging technologies for early localised prostate cancer, a systematic review. Health Technol Assess. 2003;7:iii, ix-x, 1-157.
9. Fleming C, Wasson JH, Albertsen PC, Barry MJ, Wennberg JE. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. Prostate Patient Outcomes Research Team. JAMA. 1993;269:2650-2658.
10. Sandler HM, Pajak TF, Hanks GE, Porter AT, Desilvio M, Shipley WU. Can biochemical failure (ASTRO definition) be used as a surrogate endpoint for prostate cancer survival in Phase III localized prostate cancer clinical trials? Analysis of RTOG Protocol 92-02 [abstract 1528]. Proc Am Soc Clin Oncol. 2003;22:381.
11. Owen JB, Grigsby PW, Caldwell TM, et al. Can costs be measured and predicted by modeling within a cooperative clinical trials group? Economic methodologic pilot studies of the Radiation Therapy Oncology Group (RTOG) studies 90-03 and 91-04. Int J Radiat Oncol Biol Phys. 2001;49:633-639.
12. Lipscomb J, Weinstein MC, Torrance GW. Time preference. In: Gold M, Siegel JE, Russell LB, Weinstein MC, editors. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996:214-235.
13. Piper NY, Kusada L, Lance R, Foley J, Moul J, Seay T. Adenocarcinoma of the prostate: an expensive way to die. Prostate Cancer Prostatic Dis. 2002;5:164-166.
14. Bennett CL, Matchar D, McCrory D, McLeod DG, Crawford ED, Hillner BE. Cost-effective models for flutamide for prostate carcinoma patients: are they helpful to policy makers? Cancer. 1996;77:1854-1861.
15. Saigal CS, Gornbein J, Nease R, Litwin MS. Predictors of utilities for health states in early stage prostate cancer. J Urol. 2001;166:942-946.
16. Neymark N, Adriaenssen I, Gorlia T, Caleo S, Bolla M. Estimating survival gain for economic evaluations with survival time as principal endpoint: a cost-effectiveness analysis of adding early hormonal therapy to radiotherapy in patients with locally advanced prostate cancer. Health Econ. 2002;11:233-248.
17. Feigenberg SJ, Hanlon AL, Horwitz EM, Pollack A. Androgen deprivation increases late morbidity in prostate cancer patients treated with 3D conformal radiation therapy [abstract]. Int J Radiat Oncol Biol Phys. 2003;57(2 Suppl):S176.
18. Sanguined G, Agostinelli S, Foppiano F, et al. Adjuvant androgen deprivation impacts late rectal toxicity after conformal radiotherapy of prostate carcinoma. Br J Cancer. 2002;86:1843-1847.
19. Chon JK, Jacobs SC, Naslund MJ. The cost value of medical versus surgical hormonal therapy for metastatic prostate cancer. J Urol. 2000;164(3 Pt 1):735-737.
20. Clark JA, Wray NP, Ashton CM. Living with treatment decisions: regrets and quality of life among men treated for metastatic prostate cancer. J Clin Oncol. 2001;19:72-80.
21. Diamond TH, Bucci J, Kersley JH, Asian P, Lynch WB, Bryant C. Osteoporosis and spinal fractures in men with prostate cancer: risk factors and effects of androgen deprivation therapy. J Urol 2004;172:529-532.
22. Diamond TH, Higano CS, Smith MR, Guise TA, Singer FR. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer. 2004;100:892-899.
23. Deng JH, Yang LP, Wang LS, Zhou DF. Effect of androgen deprivation therapy on bone mineral density in prostate cancer patients. Asian J Androl. 2004;6:75-77.